CCND1 and colonic neoplasm: These results suggest targeting Cdc42 with the small molecule inhibitor AZA197 in colon cancer cells can effectively modulate PAK/ERK signaling interfering with Cyclin D1 expression to affect colon cancer cell proliferation.